Overseas Media Delegation Visits Sinocare, Experiencing Chinese Innovation in Diabetes Management

From May 13 to 14, the "High-Quality Development of Hunan Xiangjiang New Area" media tour was held. Journalists from various international media outlets—including RSI (Swiss Italian-language TV), Associated Press (AP), Prensa Latina (Cuba), Yomiuri Shimbun, Mainichi Shimbun, Tokyo Shimbun, and ET Net — visited Xiangjiang New Area to explore its remarkable achievements in developing new productive forces and promoting high-quality growth.

International Journalists Experience “Sinocare Minute Clinic”

During the tour, the delegation visited Sinocare. The journalists explored Sinocare’s corporate culture hall, product exhibition area, and watched a corporate promotional video. At the Sinocare Diabetes Clinic, they personally experienced the “Sinocare Minute Clinic,” a chronic disease multi-index testing service, as well as AGEscan, a non-invasive diabetes risk screening solution.

Interviews with Dr. Cai Xiaohua by Mainichi Shimbun and Tokyo Shimbun

As the global healthcare industry thrives, Sinocare has emerged as a rising star attracting increasing international attention. In 2024, Sinocare’s overseas revenue reached CNY 1.865 billion. Its U.S. subsidiary PTS Diagnostics continued to be profitable, while Trividia achieved growth in both revenue and market share despite a shrinking traditional glucometer market in the U.S.

Sinocare’s wide-ranging testing capabilities cover blood glucose, uric acid, lipids, ketones, and HbA1c. Its product lines include PPL (Personal Palm Lab), PDL (Precision Desk Lab), PWS (Precision Wearable Systems), and the DDMS (Digital Diabetes Management Solution).

Prensa Latina Reporter Tries AGEscan Screening

The featured AGEscan device, launched in 2019 as part of the PDL product line, detects advanced glycation end-products (AGEs) in the eye lens to assess diabetes risk non-invasively. This technology transforms traditional blood-based testing into a safe, needle-free experience. With just a 6-second scan, it generates a detailed report. It requires no blood draw, no reagents, and is easy and convenient to use.

Beyond technology, Sinocare has developed a comprehensive digital diabetes management model by integrating biosensors, IoT, smart healthcare, and healthy lifestyle guidance to provide patients with personalized, holistic care. In China, over 50% of people who self-monitor their diabetes use Sinocare products, demonstrating its significant market influence. Globally, Sinocare serves more than 25 million users across 187 countries and regions.

Prensa Latina Original Coverage

Isaura Diez Millan from Prensa Latina was deeply impressed. “There are many trendy and innovative tech companies in Changsha’s Xiangjiang New Area. At Sinocare, I learned about cutting-edge diabetes technologies. Sinocare also collaborates with many countries around the world — including my homeland, Cuba,” she said. When asked to sum up her experience in one word, she chose: "Development."

Sinocare Featured in Reference News

During the visit, journalists from Prensa Latina, Mainichi Shimbun, and Tokyo Shimbun interviewed Dr. Cai Xiaohua, Sinocare Chief Scientist. They discussed the global state of diabetes and chronic disease, Sinocare’s corporate development, and future innovation strategies. Prensa Latina’s report based on this interview was later republished in Reference News under the Chinese headline: “Chinese Enterprises Empower Diabetes Diagnosis and Monitoring.”

Sinocare Captured by AP Photojournalists

With its strengths in technological innovation, diverse product portfolio, global expansion, and social responsibility, Sinocare offered the media delegation a close-up view of a Chinese company that is “rooted in China, reaching the world.” As a vivid example of innovation-driven development, Sinocare showcases Xiangjiang New Area’s excellence in scientific progress, industrial upgrading, and cultural integration— delivering to the world a powerful message of China’s high-quality development and the vitality of Chinese modernization.